primaquine [Ligand Id: 9952] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL506 (Primaquine, SN-13272, WR-2975, NSC-27296)
  • Chloroquine resistance transporter in Plasmodium falciparum [ChEMBL: CHEMBL1795182] [UniProtKB: Q9N623]
  • This target only has 0 pki data point
  • 0
1 CHEMBL506_lig_chart_1 Chloroquine resistance transporter Plasmodium falciparum
There should be some charts here, you may need to enable JavaScript!
  • CYP1A2/Cytochrome P450 1A2 in Human [ChEMBL: CHEMBL3356] [GtoPdb: 1319] [UniProtKB: P05177]
  • This target only has 0 pki data point
  • 0
2 CHEMBL506_lig_chart_2 Cytochrome P450 1A2 Human
There should be some charts here, you may need to enable JavaScript!
  • GroEL/GroES in Escherichia coli [ChEMBL: CHEMBL4106139] [UniProtKB: Q548M1, Q7BGE6]
  • This target only has 0 pki data point
  • 0
3 CHEMBL506_lig_chart_3 GroEL/GroES Escherichia coli
There should be some charts here, you may need to enable JavaScript!
4 CHEMBL506_lig_chart_4 HSP60/HSP10 Human
There should be some charts here, you may need to enable JavaScript!
  • Monoamine oxidase A in Human [ChEMBL: CHEMBL1951] [GtoPdb: 2489] [UniProtKB: P21397]
  • This target only has 0 pki data point
  • 0
5 CHEMBL506_lig_chart_5 Monoamine oxidase A Human
There should be some charts here, you may need to enable JavaScript!
  • Monoamine oxidase B in Human [ChEMBL: CHEMBL2039] [GtoPdb: 2490] [UniProtKB: P27338]
  • This target only has 0 pki data point
  • 0
6 CHEMBL506_lig_chart_6 Monoamine oxidase B Human
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium berghei [ChEMBL: CHEMBL612653]
  • This target only has 0 pki data point
  • 0
7 CHEMBL506_lig_chart_7 Plasmodium berghei Plasmodium berghei
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium falciparum [ChEMBL: CHEMBL364]
  • This target only has 0 pki data point
  • 0
8 CHEMBL506_lig_chart_8 Plasmodium falciparum Plasmodium falciparum
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium falciparum 3D7 [ChEMBL: CHEMBL2366922]
  • This target only has 0 pki data point
  • 0
9 CHEMBL506_lig_chart_9 Plasmodium falciparum 3D7 Plasmodium falciparum 3D7
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium falciparum (isolate FcB1 / Columbia) in Plasmodium falciparum FcB1/Columbia [ChEMBL: CHEMBL612608]
  • This target only has 0 pki data point
  • 0
10 CHEMBL506_lig_chart_10 Plasmodium falciparum (isolate FcB1 / Columbia) Plasmodium falciparum FcB1/Columbia
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium falciparum (isolate K1 / Thailand) in Plasmodium falciparum K1 [ChEMBL: CHEMBL612856]
  • This target only has 0 pki data point
  • 0
11 CHEMBL506_lig_chart_11 Plasmodium falciparum (isolate K1 / Thailand) Plasmodium falciparum K1
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium falciparum NF54 [ChEMBL: CHEMBL2367131]
  • This target only has 0 pki data point
  • 0
12 CHEMBL506_lig_chart_12 Plasmodium falciparum NF54 Plasmodium falciparum NF54
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium yoelii [ChEMBL: CHEMBL612889]
  • This target only has 0 pki data point
  • 0
13 CHEMBL506_lig_chart_13 Plasmodium yoelii Plasmodium yoelii
There should be some charts here, you may need to enable JavaScript!
  • Plasmodium yoelii yoelii [ChEMBL: CHEMBL612328]
  • This target only has 0 pki data point
  • 0
14 CHEMBL506_lig_chart_14 Plasmodium yoelii yoelii Plasmodium yoelii yoelii
There should be some charts here, you may need to enable JavaScript!
  • Quinone reductase 2 in Human [ChEMBL: CHEMBL3959] [UniProtKB: P16083]
  • This target only has 0 pki data point
  • 0
15 CHEMBL506_lig_chart_15 Quinone reductase 2 Human
There should be some charts here, you may need to enable JavaScript!
  • Serine hydroxymethyltransferase, mitochondrial in Human [ChEMBL: CHEMBL4295747] [UniProtKB: P34897]
  • This target only has 0 pki data point
  • 0
16 CHEMBL506_lig_chart_16 Serine hydroxymethyltransferase, mitochondrial Human
There should be some charts here, you may need to enable JavaScript!
  • SERT/Serotonin transporter in Human [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645]
  • This target only has 1 pki data point
  • 8.08
17 CHEMBL506_lig_chart_17 Serotonin transporter Human
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
Chloroquine resistance transporter in Plasmodium falciparum (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1795182] [UniProtKB: Q9N623]
ChEMBL Inhibition of chloroquine-resistant Plasmodium falciparum Dd2 CRT expressed in Xenopus laevis oocytes plasma membrane assessed as reduction of [3H]-chloroquine transportation after 1 to 2 hrs B 4.17 pIC50 68000 nM IC50 ACS Med. Chem. Lett. (2014) 5: 576-581 [PMID:24900883]
CYP1A2/Cytochrome P450 1A2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3356] [GtoPdb: 1319] [UniProtKB: P05177]
ChEMBL DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) B 6.74 pIC50 182.4 nM IC50 DrugMatrix in vitro pharmacology data
GroEL/GroES in Escherichia coli (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL4106139] [UniProtKB: Q548M1, Q7BGE6]
ChEMBL Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme activity using sodium mesoxalate as substrate after 20 to 40 mins by malachite green dye based spectrometric analysis B 4.12 pIC50 75000 nM IC50 Bioorg Med Chem Lett (2019) 29: 1106-1112 [PMID:30852084]
ChEMBL Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis B 5.21 pIC50 6200 nM IC50 Bioorg Med Chem Lett (2019) 29: 1106-1112 [PMID:30852084]
HSP60/HSP10 in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL4106131] [UniProtKB: P10809, P61604]
ChEMBL Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme activity using sodium mesoxalate as substrate after 40 to 60 mins by malachite green dye based spectrometric analysis B 4 pIC50 >100000 nM IC50 Bioorg Med Chem Lett (2019) 29: 1106-1112 [PMID:30852084]
Monoamine oxidase A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1951] [GtoPdb: 2489] [UniProtKB: P21397]
ChEMBL Inhibition of human recombinant MAOA assessed as conversion of kynuramine to 4-hydroxyquinoline preincubated for 15 mins by fluorimetric assay B 4.12 pIC50 75700 nM IC50 Bioorg. Med. Chem. Lett. (2012) 22: 1701-1704 [PMID:22264472]
Monoamine oxidase B in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2039] [GtoPdb: 2490] [UniProtKB: P27338]
ChEMBL Inhibition of human recombinant MAOB assessed as conversion of kynuramine to 4-hydroxyquinoline preincubated for 15 mins by fluorimetric assay B 4.02 pIC50 94500 nM IC50 Bioorg. Med. Chem. Lett. (2012) 22: 1701-1704 [PMID:22264472]
Plasmodium berghei (target type: ORGANISM) [ChEMBL: CHEMBL612653]
ChEMBL Antiplasmodial activity against liver stage chloroquine-susceptible Plasmodium berghei 1052 C11 infected in HepG2 cells after 44 hrs by TopCount microplate luminescence assay F 4.76 pIC50 17200 nM IC50 Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120]
ChEMBL Antimalarial activity against liver stages of Plasmodium berghei F 4.89 pIC50 13000 nM IC50 J. Med. Chem. (2012) 55: 995-1012 [PMID:22122518]
ChEMBL Antiplasmodial activity against liver stage Plasmodium berghei infected in Huh7 cells assessed as inhibition of parasite infection incubated for 1 hr prior to infection measured at 24 hrs by luciferase reporter gene assay F 5.02 pIC50 9500 nM IC50 Bioorg. Med. Chem. (2016) 24: 1786-1792 [PMID:26968650]
ChEMBL Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay F 5.07 pIC50 8428 nM IC50 Eur. J. Med. Chem. (2015) 101: 266-273 [PMID:26142491]
ChEMBL Antimalarial activity against GFP-fused Plasmodium berghei ANKA liver stage infected in HuH7 cells pretreated for 1 hr followed by parasite infection after 48 hrs by luciferase reporter gene assay F 5.07 pIC50 8420 nM IC50 J Med Chem (2017) 60: 1432-1448 [PMID:28094524]
ChEMBL Antimalarial activity against Plasmodium berghei infected in human Huh7 cells after 1 hr by luciferase reporter gene assay F 5.08 pIC50 8400 nM IC50 Eur J Med Chem (2019) 182: 111640-111640 [PMID:31472472]
ChEMBL Antiplasmodial activity against liver stage luciferase expressing Plasmodium berghei sporozoites infected in human Huh7 cells preincubated with host cells for 1 hr followed by plasmodium infection by bioluminescence assay F 5.08 pIC50 8400 nM IC50 Eur J Med Chem (2020) 187: 111927-111927 [PMID:31812035]
ChEMBL Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP-Luc infected in HuH7 cells incubated at 1 hr prior to infection followed by compound replenisment at 24 hrs post-infection measured after 48 hrs by Alamar blue assay F 5.1 pIC50 8000 nM IC50 Bioorg. Med. Chem. Lett. (2013) 23: 610-613 [PMID:23290049]
ChEMBL Antiplasmodial activity against liver stage of Plasmodium berghei sporozoites expressing firefly luciferase infected in human Huh7 cells assessed as inhibition of parasite development treated 1 hr prior to infection followed by compound replenisment at 24 hrs post-infection measured 48 hrs after infection by bioluminescence analysis F 5.12 pIC50 7500 nM IC50 MedChemComm (2012) 3: 1170-1172
ChEMBL Antimalarial activity against Plasmodium berghei infected in human HuH7 cells assessed as inhibition of liver cell infection F 5.12 pIC50 7500 nM IC50 Bioorg. Med. Chem. (2015) 23: 5098-5119 [PMID:25593097]
ChEMBL Antiplasmodial activity against Plasmodium berghei liver stage form transfected in human Huh-7 cells assessed as cell viability after 48 hrs by luciferase reporter gene assay F 5.12 pIC50 7500 nM IC50 J. Med. Chem. (2013) 56: 556-567 [PMID:23273038]
ChEMBL Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay F 5.12 pIC50 7500 nM IC50 J. Med. Chem. (2013) 56: 4811-4815 [PMID:23701465]
ChEMBL Antiplasmodial activity against liver stage of Plasmodium berghei ANKA infected in human HepG2 cells F 5.12 pIC50 7500 nM IC50 J. Nat. Prod. (2013) 76: 1064-1070 [PMID:23806111]
ChEMBL Antiplasmodial activity against liver stage of Plasmodium berghei expressing GFP infected in human Huh7 cells by luminescence assay F 5.12 pIC50 7500 nM IC50 J. Nat. Prod. (2013) 76: 1064-1070 [PMID:23806111]
ChEMBL Antiplasmodial activity against liver stage of Plasmodium berghei infected in human HuH7 cells assessed as parasite growth inhibition incubated for 1 hr prior to parasite infection measured after 48 hrs F 5.12 pIC50 7500 nM IC50 J. Med. Chem. (2013) 56: 7679-7690 [PMID:24020770]
ChEMBL Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei expressing luciferase and GFP infected in human HuH7 cells assessed as inhibition of parasite development incubated for 1 hr prior to parasite infection measured after 48 hrs by Alamar blue assay F 5.12 pIC50 7500 nM IC50 Eur. J. Med. Chem. (2013) 69: 872-880 [PMID:24125849]
ChEMBL Antimalarial activity against liver stage of Plasmodium berghei infected in human Huh7 cells after 48 hrs by luciferase assay F 5.12 pIC50 7500 nM IC50 ACS Med. Chem. Lett. (2014) 5: 108-112 [PMID:24900781]
ChEMBL Antimalarial activity against liver stage form of luciferase transfected Plasmodium berghei sporozoites infected in human HuH7 cells preincubated with host cells for 1 hr followed by plasmodial infection and measured after 48 hrs by bioluminescence method F 5.2 pIC50 6250 nM IC50 J Med Chem (2019) 62: 1022-1035 [PMID:30562027]
ChEMBL Antiplasmodial activity against GFP-harboring Plasmodium berghei sporozoites infected in human HepG2 cells assessed as reduction in parasite growth treated every 24 hrs by DAPI staining-based fluorescence microscopic analysis F 5.44 pIC50 3650 nM IC50 Eur J Med Chem (2018) 158: 68-81 [PMID:30199706]
ChEMBL Antiplasmodial activity against GFP-fused Plasmodium berghei sporozoites infected in human HepG2A16 cells treated simultaneously with infection by fluorescence microscopic analysis F 5.44 pIC50 3650 nM IC50 Eur J Med Chem (2018) 152: 489-514 [PMID:29754074]
ChEMBL Antiplasmodial activity against luciferase expressing Plasmodium berghei sporozoites infected in human HuH7 cells assessed as reduction in parasite load incubated prior to parasite infection and measured after 48 hrs by bioluminescence assay F 5.62 pIC50 2400 nM IC50 J Med Chem (2020) 63: 1750-1762 [PMID:32011136]
ChEMBL Antiplasmodial activity against liver-stage GFP expressing Plasmodium berghei sporozoites infected in human HuH7 cells assessed as inhibition of parasite schizonts development after 48 hrs by FACS analysis F 5.7 pIC50 2000 nM IC50 J. Med. Chem. (2009) 52: 7800-7807 [PMID:19799426]
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364]
ChEMBL Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 F 5 pIC50 >10000 nM IC50 Bioorg. Med. Chem. Lett. (2007) 17: 6101-6106 [PMID:17900897]
ChEMBL Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis F 5.01 pIC50 9860 nM IC50 Eur J Med Chem (2018) 158: 68-81 [PMID:30199706]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes after 48 hrs by microscopy F 5.02 pIC50 9650 nM IC50 Bioorg. Med. Chem. Lett. (2008) 18: 4666-4669 [PMID:18653332]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by [3H]hypoxanthine uptake F 5.11 pIC50 7700 nM IC50 Bioorg. Med. Chem. Lett. (2008) 18: 4666-4669 [PMID:18653332]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcM29 after 48 hrs by [3H]hypoxanthine uptake F 5.14 pIC50 7250 nM IC50 Bioorg. Med. Chem. Lett. (2008) 18: 4666-4669 [PMID:18653332]
ChEMBL Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum F32 after 48 hrs F 5.17 pIC50 6830 nM IC50 Eur. J. Med. Chem. (2010) 45: 2854-2859 [PMID:20362359]
ChEMBL Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum F32 after 48 hrs by [3H]hypoxanthine uptake F 5.17 pIC50 6830 nM IC50 Bioorg. Med. Chem. Lett. (2008) 18: 4666-4669 [PMID:18653332]
ChEMBL Antimalarial activity against asexual stage of Plasmodium falciparum 3D7 after 72 hrs by image-based HTS assay F 5.22 pIC50 6090 nM IC50 J. Med. Chem. (2013) 56: 7727-7740 [PMID:23927763]
ChEMBL Antimalarial activity against early (1 to 3) gametocytic stage of Plasmodium falciparum after 72 hrs by image-based HTS assay F 5.23 pIC50 5860 nM IC50 J. Med. Chem. (2013) 56: 7727-7740 [PMID:23927763]
ChEMBL Antimalarial activity against asexual blood stage of chloroquine-susceptible Plasmodium falciparum 3D7 infected in human erythrocytes by [3H]-Hypoxanthine uptake assay F 5.24 pIC50 5770 nM IC50 Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120]
ChEMBL Antimalarial activity against asexual blood stage of chloroquine-susceptible Plasmodium falciparum D6 infected in human erythrocytes by [3H]-Hypoxanthine uptake assay F 5.29 pIC50 5160 nM IC50 Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120]
ChEMBL Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 2 & 3) F 5.34 pIC50 4580 nM IC50 Antimicrob. Agents Chemother. (2007) 51: 1463-1472 [PMID:17242150]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 F 5.48 pIC50 3340 nM IC50 Bioorg. Med. Chem. Lett. (2008) 18: 485-488 [PMID:18077165]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 F 5.48 pIC50 3300 nM IC50 Bioorg. Med. Chem. Lett. (2008) 18: 4150-4153 [PMID:18539459]
ChEMBL Antimalarial activity against chloroquine-resistant erythrocyte stage of Plasmodium falciparum W2 after 48 hrs F 5.48 pIC50 3300 nM IC50 ACS Med. Chem. Lett. (2014) 5: 108-112 [PMID:24900781]
ChEMBL Antiplasmodial activity against chloroquine-resistant blood stage Plasmodium falciparum W2 after 48 hrs by FACS analysis F 5.48 pIC50 3300 nM IC50 J. Med. Chem. (2009) 52: 7800-7807 [PMID:19799426]
ChEMBL Antimalarial activity against asexual blood stage of chloroquine-resistant Plasmodium falciparum W2 infected in human erythrocytes by [3H]-Hypoxanthine uptake assay F 5.63 pIC50 2350 nM IC50 Bioorg Med Chem Lett (2017) 27: 4597-4600 [PMID:28939120]
ChEMBL Antimalarial activity against Plasmodium falciparum KT3 gametocytes F 5.68 pIC50 2100 nM IC50 J. Med. Chem. (2012) 55: 10328-10344 [PMID:23075290]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells after 48 hrs by SYBR test F 5.72 pIC50 1890 nM IC50 Bioorg. Med. Chem. Lett. (2016) 26: 1881-1884 [PMID:26988303]
ChEMBL Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 gametocytes (stage 4 & 5) F 5.81 pIC50 1540 nM IC50 Antimicrob. Agents Chemother. (2007) 51: 1463-1472 [PMID:17242150]
ChEMBL Antimalarial activity against multidrug-resistant Plasmodium falciparum W2 by SYBR green-based assay F 5.83 pIC50 1470 nM IC50 Bioorg. Med. Chem. Lett. (2015) 25: 1100-1103 [PMID:25650255]
ChEMBL Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 asexual gametocytes F 5.88 pIC50 1320 nM IC50 Antimicrob. Agents Chemother. (2007) 51: 1463-1472 [PMID:17242150]
ChEMBL Antiplasmodial activity against multidrug-resistant Plasmodium falciparum FCR-3 by [3H]-hypoxanthine incorporation assay F 5.93 pIC50 1180 nM IC50 Eur J Med Chem (2018) 152: 489-514 [PMID:29754074]
ChEMBL Antiplasmodial activity against the multidrug-resistant Plasmodium falciparum FRC-3 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis F 5.96 pIC50 1100 nM IC50 Eur J Med Chem (2018) 158: 68-81 [PMID:30199706]
ChEMBL Antimalarial activity against Plasmodium falciparum KT1 gametocytes F 6.1 pIC50 800 nM IC50 J. Med. Chem. (2012) 55: 10328-10344 [PMID:23075290]
ChEMBL Antiplasmodial activity against Plasmodium falciparum FCR-3 sporozoites infected in human primary hepatocytes treated simultaneously with infection by DAPI staining based HCS analysis F 6.4 pIC50 400 nM IC50 Eur J Med Chem (2018) 152: 489-514 [PMID:29754074]
ChEMBL Antiplasmodial activity against GFP-harboring Plasmodium falciparum sporozoites infected in human primary hepatocytes assessed as reduction in parasite growth treated every 24 hrs by DAPI staining-based fluorescence microscopic analysis F 6.4 pIC50 400 nM IC50 Eur J Med Chem (2018) 158: 68-81 [PMID:30199706]
ChEMBL Antiplasmodial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine incorporation assay F 6.49 pIC50 326 nM IC50 Antimicrob. Agents Chemother. (2009) 53: 3131-3134 [PMID:19364853]
ChEMBL Antiplasmodial activity against multidrug-resistant Plasmodium falciparum VS/1 by [3H]hypoxanthine incorporation assay F 6.49 pIC50 326 nM IC50 Antimicrob. Agents Chemother. (2009) 53: 3131-3134 [PMID:19364853]
ChEMBL Antiplasmodial activity against Plasmodium falciparum W2 gametocytes assessed as suppression of parasitemia after 4 hrs by Giemsa staining F 8.05 pIC50 8.9 nM IC50 Antimicrob. Agents Chemother. (2009) 53: 4393-4398 [PMID:19667291]
ChEMBL Antiplasmodial activity against Plasmodium falciparum W2 assessed as suppression of parasitemia after 4 hrs by Giemsa staining F 8.15 pIC50 7.14 nM IC50 Antimicrob. Agents Chemother. (2009) 53: 4393-4398 [PMID:19667291]
ChEMBL Antiplasmodial activity against Plasmodium falciparum F32 assessed as suppression of parasitemia after 4 hrs by Giemsa staining F 8.21 pIC50 6.17 nM IC50 Antimicrob. Agents Chemother. (2009) 53: 4393-4398 [PMID:19667291]
Plasmodium falciparum 3D7 (target type: ORGANISM) [ChEMBL: CHEMBL2366922]
ChEMBL Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum 3D7 F 6.34 pIC50 460 nM IC50 Eur. J. Med. Chem. (2015) 90: 280-295 [PMID:25461328]
Plasmodium falciparum (isolate FcB1 / Columbia) in Plasmodium falciparum FcB1/Columbia (target type: ORGANISM) [ChEMBL: CHEMBL612608]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1 after 48 hrs by [3H]hypoxanthine uptake F 5.16 pIC50 6870 nM IC50 Bioorg. Med. Chem. Lett. (2008) 18: 4666-4669 [PMID:18653332]
ChEMBL Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1/Columbia after 48 hrs F 5.16 pIC50 6870 nM IC50 Eur. J. Med. Chem. (2010) 45: 2854-2859 [PMID:20362359]
ChEMBL Antiplasmodial activity against Plasmodium falciparum FcB1/Columbia assessed as suppression of parasitemia after 4 hrs by Giemsa staining F 8.05 pIC50 8.9 nM IC50 Antimicrob. Agents Chemother. (2009) 53: 4393-4398 [PMID:19667291]
Plasmodium falciparum (isolate K1 / Thailand) in Plasmodium falciparum K1 (target type: ORGANISM) [ChEMBL: CHEMBL612856]
ChEMBL Antimalarial activity against Plasmodium falciparum K1 assessed as inhibition of [3H] hypoxanthine uptake by liquid scintillation counting F 6.19 pIC50 643 nM IC50 ACS Med. Chem. Lett. (2013) 4: 128-131 [PMID:24900574]
ChEMBL Antimicrobial activity against chloroquine-resistant Plasmodium falciparum K1 F 6.34 pIC50 460 nM IC50 Eur. J. Med. Chem. (2015) 90: 280-295 [PMID:25461328]
Plasmodium falciparum NF54 (target type: ORGANISM) [ChEMBL: CHEMBL2367131]
ChEMBL Antiplasmodial activity against blood stage of chloroquine-sensitive Plasmodium falciparum NF54 by parasite lactate dehydrogenase assay F 6.05 pIC50 892 nM IC50 Eur. J. Med. Chem. (2015) 101: 266-273 [PMID:26142491]
Plasmodium yoelii (target type: ORGANISM) [ChEMBL: CHEMBL612889]
ChEMBL Antiplasmodial activity against GFP-harboring Plasmodium yoelii sporozoites infected in human HepG2 cells expressing CD81 assessed as reduction in parasite growth treated every 24 hrs by DAPI staining-based fluorescence microscopic analysis F 5.67 pIC50 2130 nM IC50 Eur J Med Chem (2018) 158: 68-81 [PMID:30199706]
ChEMBL Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis F 5.94 pIC50 1160 nM IC50 Eur. J. Med. Chem. (2015) 95: 16-28 [PMID:25791675]
ChEMBL Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin F 6 pIC50 <1000 nM IC50 J. Med. Chem. (2013) 56: 7761-7771 [PMID:23927658]
ChEMBL Antimalarial activity against liver stages of Plasmodium yoelii 265 BY infected in Swiss mouse after 48 hrs by fluorescence microscopy F 7.12 pIC50 75 nM IC50 J. Med. Chem. (2012) 55: 995-1012 [PMID:22122518]
Plasmodium yoelii yoelii (target type: ORGANISM) [ChEMBL: CHEMBL612328]
ChEMBL Antimalarial activity against Plasmodium yoelii 265 sporozoites in primary mice (Mus musculus) hepatocytes after 48 hrs F 6.19 pIC50 640 nM IC50 Bioorg. Med. Chem. (2008) 16: 6186-6192 [PMID:18456502]
ChEMBL Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs F 7.12 pIC50 75.7 nM IC50 Antimicrob. Agents Chemother. (2008) 52: 1215-1220 [PMID:18212104]
ChEMBL Antimalarial activity against liver stages of Plasmodium yoelii yoelii F 7.12 pIC50 75.7 nM IC50 J. Med. Chem. (2012) 55: 995-1012 [PMID:22122518]
Quinone reductase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3959] [UniProtKB: P16083]
ChEMBL Inhibition of human recombinant NQO2 B 5.12 pIC50 7500 nM IC50 Bioorg. Med. Chem. Lett. (2010) 20: 7331-7336 [PMID:21074425]
Serine hydroxymethyltransferase, mitochondrial in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4295747] [UniProtKB: P34897]
ChEMBL Inhibition of His-tagged human recombinant SHMT2 expressed in Escherichia coli BLR(DE3) assessed as reduction in NADPH level using L-serine, THF and NADP+ incubated for 5 mins by SHMT2-MTHFD coupled reaction based fluorescence assay B 6.36 pIC50 436.52 nM IC50 WO-2016085990-A1. Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity (null)
SERT/Serotonin transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645]
ChEMBL DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) B 8.08 pKi 8.4 nM Ki DrugMatrix in vitro pharmacology data
ChEMBL DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) B 7.8 pIC50 16 nM IC50 DrugMatrix in vitro pharmacology data

ChEMBL data shown on this page come from version 28:

Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F, Bellis LJ, Cibrián-Uhalte E, Davies M, Dedman N, Karlsson A, Magariños MP, Overington JP, Papadatos G, Smit I, Leach AR. (2017) 'The ChEMBL database in 2017.' Nucleic Acids Res., 45(D1). DOI: 10.1093/nar/gkw1074. [PMCID:5210557]